Analysts have raised their price target for agilon health to $1.23 from $1.22 per share. This change reflects slight improvements in profit margin expectations, despite moderately lower anticipated revenue growth.
What's in the News
- The Board amended and restated the company's by-laws, with changes to officer roles and updates that reflect Delaware law changes (Company announcement).
- agilon health is suspending its previously issued full-year 2025 financial guidance due to leadership changes and market uncertainty (Company announcement).
- CEO Steven Sell has stepped down. The Board is conducting a search for a permanent CEO with the help of an executive search firm (Company announcement).
Valuation Changes
- Consensus Analyst Price Target has risen slightly. It is now $1.23, up from $1.22 per share.
- Discount Rate remains unchanged at 6.78%.
- Revenue Growth expectation has fallen moderately, decreasing from 7.87% to 7.54%.
- Net Profit Margin forecast has increased slightly, rising from 5.28% to 5.38%.
- Future P/E has edged up, moving from 1.59x to 1.60x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.